Loading...

Ovoca Bio

ISE:OVXA
Snowflake Description

Flawless balance sheet and overvalued.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
OVXA
ISE
€5M
Market Cap
  1. Home
  2. IE
  3. Pharmaceuticals & Biotech
Company description

Ovoca Bio plc focuses on development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. The last earnings update was 236 days ago. More info.


Add to Portfolio Compare Print
  • Ovoca Bio has significant price volatility in the past 3 months.
OVXA Share Price and Events
7 Day Returns
0%
ISE:OVXA
1.9%
Europe Pharmaceuticals
-0%
IE Market
1 Year Returns
-40%
ISE:OVXA
2%
Europe Pharmaceuticals
-13.6%
IE Market
OVXA Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Ovoca Bio (OVXA) 0% -33% -20% -40% 9.1% -29.4%
Europe Pharmaceuticals 1.9% 1.2% -4.6% 2% 3.3% 5%
IE Market -0% -5.3% 1.6% -13.6% 0.7% 39.8%
1 Year Return vs Industry and Market
  • OVXA underperformed the Pharmaceuticals industry which returned 2% over the past year.
  • OVXA underperformed the Market in Ireland which returned -13.6% over the past year.
Price Volatility
OVXA
Industry
5yr Volatility vs Market
Related Companies

Sorry, no analysis for Ovoca Bio's competitors could be found in our database.

OVXA Value

 Is Ovoca Bio undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Ovoca Bio. This is due to cash flow or dividend data being unavailable. The share price is €0.06.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Ovoca Bio's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Ovoca Bio's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
ISE:OVXA PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.02
ISE:OVXA Share Price ** ISE (2019-05-08) in EUR €0.06
Europe Pharmaceuticals Industry PE Ratio Median Figure of 43 Publicly-Listed Pharmaceuticals Companies 21.72x
Ireland Market PE Ratio Median Figure of 23 Publicly-Listed Companies 11.42x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Ovoca Bio.

ISE:OVXA PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= ISE:OVXA Share Price ÷ EPS (both in EUR)

= 0.06 ÷ -0.02

-3.42x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ovoca Bio is loss making, we can't compare its value to the Europe Pharmaceuticals industry average.
  • Ovoca Bio is loss making, we can't compare the value of its earnings to the Ireland market.
Price based on expected Growth
Does Ovoca Bio's expected growth come at a high price?
Raw Data
ISE:OVXA PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -3.42x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Pharmaceuticals Industry PEG Ratio Median Figure of 35 Publicly-Listed Pharmaceuticals Companies 1.83x
Ireland Market PEG Ratio Median Figure of 19 Publicly-Listed Companies 0.99x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Ovoca Bio, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Ovoca Bio's assets?
Raw Data
ISE:OVXA PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.22
ISE:OVXA Share Price * ISE (2019-05-08) in EUR €0.06
Europe Pharmaceuticals Industry PB Ratio Median Figure of 94 Publicly-Listed Pharmaceuticals Companies 2.96x
Ireland Market PB Ratio Median Figure of 33 Publicly-Listed Companies 1.15x
ISE:OVXA PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= ISE:OVXA Share Price ÷ Book Value per Share (both in EUR)

= 0.06 ÷ 0.22

0.27x

* Primary Listing of Ovoca Bio.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Ovoca Bio is good value based on assets compared to the Europe Pharmaceuticals industry average.
X
Value checks
We assess Ovoca Bio's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Pharmaceuticals industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Pharmaceuticals industry average (and greater than 0)? (1 check)
  5. Ovoca Bio has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

OVXA Future Performance

 How is Ovoca Bio expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Ovoca Bio has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
12.6%
Expected Pharmaceuticals industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Ovoca Bio expected to grow at an attractive rate?
  • Unable to compare Ovoca Bio's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare Ovoca Bio's earnings growth to the Ireland market average as no estimate data is available.
  • Unable to compare Ovoca Bio's revenue growth to the Ireland market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
ISE:OVXA Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Pharmaceuticals Industry Earnings Growth Rate Market Cap Weighted Average 12.6%
Europe Pharmaceuticals Industry Revenue Growth Rate Market Cap Weighted Average 4.6%
Ireland Market Earnings Growth Rate Market Cap Weighted Average 11.9%
Ireland Market Revenue Growth Rate Market Cap Weighted Average 5.2%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
ISE:OVXA Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
ISE:OVXA Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 -1 -1
2018-03-31 -1 -1
2017-12-31 -1 0
2017-09-30 -1 1
2017-06-30 -2 2
2017-03-31 -1 0
2016-12-31 0 -1
2016-09-30 0 -2
2016-06-30 1 -3
2016-03-31 1 -3
2015-12-31 1 -2
2015-09-30 0 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if Ovoca Bio is high growth as no earnings estimate data is available.
  • Unable to determine if Ovoca Bio is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
ISE:OVXA Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (10 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from Ovoca Bio Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ISE:OVXA Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30 -0.02
2018-03-31 -0.01
2017-12-31 0.00
2017-09-30 0.01
2017-06-30 0.02
2017-03-31 0.01
2016-12-31 -0.01
2016-09-30 -0.03
2016-06-30 -0.04
2016-03-31 -0.03
2015-12-31 -0.03
2015-09-30 -0.06

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Ovoca Bio will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine Ovoca Bio's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. Ovoca Bio's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Pharmaceuticals & Biotech companies here
  3. Ovoca Bio's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess Ovoca Bio's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Ovoca Bio has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

OVXA Past Performance

  How has Ovoca Bio performed over the past 5 years?

  • Ovoca Bio's last earnings update was 236 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Ovoca Bio's growth in the last year to its industry (Pharmaceuticals).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Ovoca Bio does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Ovoca Bio's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Ovoca Bio's 1-year growth to the Europe Pharmaceuticals industry average as it is not currently profitable.
Earnings and Revenue History
Ovoca Bio's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Ovoca Bio Company Filings, last reported 10 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

ISE:OVXA Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 -1.43 1.40
2018-03-31 -0.91 1.40
2017-12-31 -0.38 1.40
2017-09-30 0.70 1.56
2017-06-30 1.78 1.71
2017-03-31 0.41 1.73
2016-12-31 -0.96 1.74
2016-09-30 -2.15 1.46
2016-06-30 -3.34 1.19
2016-03-31 -2.78 1.15
2015-12-31 -2.22 1.12
2015-09-30 -4.69 1.26
2015-06-30 -7.15 1.40
2015-03-31 -6.90 1.51
2014-12-31 -6.65 1.62
2014-09-30 -7.61 1.51
2014-06-30 -8.57 1.40
2014-03-31 -11.69 1.47
2013-12-31 -14.82 1.54
2013-09-30 -10.84 1.99
2013-06-30 -6.86 2.45
2013-03-31 -4.55 2.47
2012-12-31 -2.23 2.49
2012-09-30 -3.65 2.86
2012-06-30 -5.07 3.23

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Ovoca Bio has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Ovoca Bio has efficiently used its assets last year compared to the Europe Pharmaceuticals industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Ovoca Bio improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Ovoca Bio's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Pharmaceuticals industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Ovoca Bio has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

OVXA Health

 How is Ovoca Bio's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Ovoca Bio's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Ovoca Bio is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Ovoca Bio has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Ovoca Bio's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Ovoca Bio has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Ovoca Bio Company Filings, last reported 10 months ago.

ISE:OVXA Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 18.06 0.00 5.14
2018-03-31 18.06 0.00 5.14
2017-12-31 22.40 0.00 5.55
2017-09-30 22.40 0.00 5.55
2017-06-30 22.24 0.00 6.39
2017-03-31 22.24 0.00 6.39
2016-12-31 23.47 0.00 6.74
2016-09-30 23.47 0.00 6.74
2016-06-30 27.86 0.00 7.51
2016-03-31 27.86 0.00 7.51
2015-12-31 21.45 0.00 7.34
2015-09-30 21.45 0.00 7.34
2015-06-30 22.51 0.00 7.41
2015-03-31 22.51 0.00 7.41
2014-12-31 22.46 0.00 7.29
2014-09-30 22.46 0.00 7.29
2014-06-30 26.25 0.00 9.17
2014-03-31 26.25 0.00 9.17
2013-12-31 25.97 0.00 14.07
2013-09-30 25.97 0.00 14.07
2013-06-30 35.03 0.00 15.44
2013-03-31 35.03 0.00 15.44
2012-12-31 48.63 0.00 15.93
2012-09-30 48.63 0.00 15.93
2012-06-30 47.97 0.00 20.40
  • Ovoca Bio has no debt.
  • Ovoca Bio has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Ovoca Bio has sufficient cash runway for more than 3 years based on current free cash flow.
  • Ovoca Bio has sufficient cash runway for more than 3 years if free cash flow continues to grow at historical rates of 89.2% each year.
X
Financial health checks
We assess Ovoca Bio's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Ovoca Bio has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

OVXA Dividends

 What is Ovoca Bio's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Ovoca Bio dividends.
If you bought €2,000 of Ovoca Bio shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Ovoca Bio's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Ovoca Bio's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
ISE:OVXA Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Pharmaceuticals Industry Average Dividend Yield Market Cap Weighted Average of 32 Stocks 3.4%
Ireland Market Average Dividend Yield Market Cap Weighted Average of 21 Stocks 2.4%
Ireland Minimum Threshold Dividend Yield 10th Percentile 1.2%
Ireland Bottom 25% Dividend Yield 25th Percentile 2.2%
Ireland Top 25% Dividend Yield 75th Percentile 4.1%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Ovoca Bio has not reported any payouts.
  • Unable to verify if Ovoca Bio's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Ovoca Bio's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Ovoca Bio has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Ovoca Bio's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Ovoca Bio afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Ovoca Bio has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

OVXA Management

 What is the CEO of Ovoca Bio's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Kirill Golovanov
COMPENSATION €164,000
AGE 40
TENURE AS CEO 7 years
CEO Bio

Mr. Kirill Golovanov has been the Chief Executive Officer at Ovoca Gold plc since May 2012. Mr. Golovanov has been Corporate Secretary of Ovoca Gold plc since March 2010. Mr. Golovanov joined Ovoca as a corporate advisor in 2007 and moved to be the manager of its Russia representative office in 2009. During his time at Ovoca he played a major role in the development and subsequent sale of the Goltsovoye silver deposit. He has extensive experience in mining and corporate law, as well as working experience at leading Russian enterprises, such as Gazprombank and Vneshekonombank. Additionally, he was a department manager in the Federal Service on Bankruptcy and Finance Restoration - a subdivision of the Russian Federation Ministry of Finance. He serves as an Executive Director of Ovoca Gold plc. He served as a Non-Executive Director of Ovoca Gold plc since April 12, 2012. He has JD from Moscow State Legal Academy, Moscow Russia.

CEO Compensation
  • Kirill's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Kirill's remuneration is higher than average for companies of similar size in Ireland.
Management Team

Mikhail Mogutov

TITLE
Executive Chairman
COMPENSATION
€106K

Kirill Golovanov

TITLE
CEO, Company Secretary & Executive Director
COMPENSATION
€164K
AGE
40
TENURE
7 yrs

Svetlana Radchenko

TITLE
Chief Financial Officer
TENURE
9.2 yrs
Board of Directors Tenure

Average tenure and age of the Ovoca Bio board of directors in years:

8.2
Average Tenure
53
Average Age
  • The tenure for the Ovoca Bio board of directors is about average.
Board of Directors

Kirill Golovanov

TITLE
CEO, Company Secretary & Executive Director
COMPENSATION
€164K
AGE
40
TENURE
7 yrs

Leonid Skoptsov

TITLE
Non-Executive Director
COMPENSATION
€106K
AGE
61
TENURE
12.9 yrs

Mikhail Mogutov

TITLE
Executive Chairman
COMPENSATION
€106K
TENURE
9.4 yrs

Yuri Radchenko

TITLE
Non-Executive Director
COMPENSATION
€16K
AGE
66
TENURE
12.9 yrs

Tim McCutcheon

TITLE
Non-Executive Director
COMPENSATION
€16K
AGE
45
TENURE
10.3 yrs

Romulo Colindres

TITLE
Non-Executive Director
TENURE
0.8 yrs

Nikolay Myasoedov

TITLE
Non-Executive Director
TENURE
0.8 yrs

Christopher Wiltshire

TITLE
Non-Executive Director
TENURE
0.8 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Ovoca Bio's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Ovoca Bio has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

OVXA News

Simply Wall St News

Does The Ovoca Bio plc (ISE:OVXA) Share Price Fall With The Market?

Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … A stock with a beta below one is either less volatile than the market, or more volatile but not corellated with the overall market. … In comparison a stock with a beta of over one tends to be move in a similar direction to the market in the long term, but with greater changes in price.

Simply Wall St -

Could The Ovoca Bio plc (ISE:OVXA) Ownership Structure Tell Us Something Useful?

The big shareholder groups in Ovoca Bio plc (ISE:OVXA) have power over the company. … Large companies usually have institutions as shareholders, and we usually see insiders owning shares in smaller companies. … Ovoca Bio is a smaller company with a market capitalization of €8.6m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Could The Ovoca Bio plc (ISE:OVXA) Ownership Structure Tell Us Something Useful?

A look at the shareholders of Ovoca Bio plc (ISE:OVXA) can tell us which group is most powerful. … Generally speaking, as a company grows, institutions will increase their ownership. … Ovoca Bio is a smaller company with a market capitalization of €7m, so it may still be flying under the radar of many institutional investors.

Simply Wall St -

Why Ovoca Gold plc's (ISE:OVXA) Ownership Structure Is Important

In this analysis, my focus will be on developing a perspective on Ovoca Gold plc’s (ISE:OVXA) latest ownership structure, a less discussed, but important factor. … The implications of these institutions’ actions can either benefit or hinder individual investors, so it is important to understand the ownership composition of your stock investment. … Check out our latest analysis for Ovoca Gold

Simply Wall St -

How Should You Think About Ovoca Gold plc's (ISE:OVXA) Risks?

View our latest analysis for Ovoca Gold An interpretation of OVXA's beta Ovoca Gold's beta of 0.19 indicates that the stock value will be less variable compared to the whole stock market. … OVXA’s beta indicates it is a stock that investors may find valuable if they want to reduce the overall market risk exposure of their stock portfolio. … How OVXA's assets could affect its beta An asset-heavy company tends to have a higher beta because the risk associated with running fixed assets during a downturn is highly expensive.

Simply Wall St -

Breaking Down Ovoca Gold plc's (ISE:OVXA) Ownership Structure

In this article, I'm going to take a look at Ovoca Gold plc’s (ISE:OVXA) latest ownership structure, a non-fundamental factor which is important, but remains a less discussed subject among investors. … See our latest analysis for Ovoca Gold ISE:OVXA Ownership_summary Mar 20th 18 Insider Ownership Another important group of shareholders are company insiders. … Insider ownership has to do more with how the company is managed and less to do with the direct impact of the magnitude of shares trading on the market.

Simply Wall St -

Why Ovoca Gold plc's (ISE:OVXA) ROE Of 7.98% Does Not Tell The Whole Story

See our latest analysis for Ovoca Gold Breaking down ROE — the mother of all ratios Return on Equity (ROE) weighs Ovoca Gold’s profit against the level of its shareholders’ equity. … Return on Equity = Net Profit ÷ Shareholders Equity ROE is measured against cost of equity in order to determine the efficiency of Ovoca Gold’s equity capital deployed. … Given a discrepancy of -1.96% between return and cost, this indicated that Ovoca Gold may be paying more for its capital than what it’s generating in return.

Simply Wall St -

OVXA Company Info

Description

Ovoca Bio plc focuses on development and commercialization of novel product candidates for the treatment of female sexual dysfunctions. It is developing Libicore, a medication for treatment of female sexual dysfunction. The company was formerly known as Ovoca Gold plc and changed its name to Ovoca Bio plc in July 2018. Ovoca Bio plc was founded in 1985 and is based in Dublin, Ireland.

Details
Name: Ovoca Bio plc
OVXA
Exchange: ISE
Founded: 1985
€4,893,828
81,563,806
Website: http://www.ovocabio.com
Address: Ovoca Bio plc
17 Pembroke Street Upper,
Dublin,
Co. Dublin, 2,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
ISE OVXA Ordinary Shares Irish Stock Exchange IE EUR 02. Jan 1992
DB OVXA Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
AIM OVB Ordinary Shares London Stock Exchange AIM Market GB GBP 02. Jan 1992
Number of employees
Current staff
Staff numbers
6
Ovoca Bio employees.
Industry
Pharmaceuticals
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/05/22 20:56
End of day share price update: 2019/05/08 00:00
Last earnings filing: 2018/09/28
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.